Pharsight

Cycloset patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866584 VEROSCIENCE Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(11 years ago)

US5468755 VEROSCIENCE Therapeutic process for the treatment of the pathologies of Type II diabetes
Nov, 2012

(11 years ago)

US5756513 VEROSCIENCE Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(11 years ago)

US5679685 VEROSCIENCE Accelerated release composition containing bromocriptine
Oct, 2014

(9 years ago)

US5716957 VEROSCIENCE Method for modifying and resetting the bloodstream prolactin levels of a human subject
Feb, 2015

(9 years ago)

US7888310 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy
Jul, 2023

(9 months ago)

US8137992 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(9 months ago)

US8137994 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(9 months ago)

US8137993 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Jul, 2023

(9 months ago)

US8877708 VEROSCIENCE Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9895422 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9352025 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US10688155 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US11000522 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US10688094 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

Cycloset is owned by Veroscience.

Cycloset contains Bromocriptine Mesylate.

Cycloset has a total of 21 drug patents out of which 9 drug patents have expired.

Expired drug patents of Cycloset are:

  • US5866584
  • US5468755
  • US5756513
  • US5679685
  • US5716957
  • US7888310
  • US8137992
  • US8137994
  • US8137993

Cycloset was authorised for market use on 05 May, 2009.

Cycloset is available in tablet;oral dosage forms.

Cycloset can be used as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27, improvement of glycemic control in adults with type 2 diabetes mellitus who have one or more specified cardiovascular risk factors, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12, adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24, improvement of glycemic control in adults with type 2 diabetes mellitus who have one or more specified cardiovascular risk factors wherein the patient has cardiovascular disease, improvement of glycemic control in individuals with type 2 diabetes, treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7.

The generics of Cycloset are possible to be released after 30 April, 2032.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Improvement of glycemic control in individuals with type 2 diabetes; Improvement of glycemic control in adults with type 2 diabetes mellitus who have one or more specified cardiovascular risk factors ...

Dosage: TABLET;ORAL

More Information on Dosage

CYCLOSET family patents

Family Patents